Q32 Bio的药物显示,在减少阿洛皮西亚草原的严重毛发损失方面,取得了可喜成果。 Q32 Bio's drug shows promising results in reducing severe hair loss from alopecia areata.

生物的药物bempikibart在治疗严重的脱发方面显示出有前途的结果. Q32 Bio's drug bempikibart showed promising results in treating severe alopecia areata. 在2a期试验中,用bempikibart治疗的患者的脱发严重程度降低了16%,而安慰剂组的减少为2%. In a Phase 2a trial, patients treated with bempikibart had a 16% reduction in hair loss severity compared to a 2% reduction in the placebo group. 这种药物阻断了某些免疫信号,也显示出病人的持久反应,其好处持续到治疗期之后。 The drug, which blocks certain immune signals, also showed durable responses in patients, with benefits lasting beyond the treatment period. 这项研究正在进行中,并计划于2025年晚些时候进行开放标签扩展。 The study's ongoing and an open-label extension are planned for later in 2025.